Alcoholic Liver Cirrhosis
6
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Long-term Follow-up Study of Livercellgram in Alcoholic LC Patients Who Completed Livercellgram Phase 2 Study
Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC
Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis
REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)
The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis
Prevention of Decompensation in Liver Cirrhosis